DTIL: Additional Pre-clinical Validation at ASGCT as We Await Cohort 1 Patient Data by YE26

Research evidence excerpt

DTIL: Additional Pre-clinical Validation at ASGCT as We Await Cohort 1 Patient Data by YE26

FLASH NOTE

May 15, 2026

Debjit Chattopadhyay, Ph.D. debjit.chattopadhyay@guggenheimpartners.com DTIL: Additional Pre-clinical Validation at ASGCT as

212 823 6584 We Await Cohort 1 Patient Data by YE26

Ry Forseth, Ph.D.

ry.forseth@guggenheimpartners.com

212 518 9226 Key Message: Company presented new preclinical early juvenile (2-week-old) murine

data at the ASGCT meeting. The data built on a pre-existing late juvenile murine Moritz Reiterer, Ph.D.

moritz.reiterer@guggenheimpartners.com dataset, which demonstrated that gene editing led to progressively increasing dystrophin

212 372 6368 restoration and muscle function. Data in early juvenile animals at 3 months and 50% lower

dose were broadly comparable to late juvenile data with respect to dystrophin restoration

Hannah Wei and dystrophin-positive muscle fiber levels, although the magnitude of responses was hannah.wei@guggenheimpartners.com

212 518 5896 greater in early juvenile animals. We are awaiting 9-month data to see if this translates

into greater functional benefit. Results support early treatment of patients and beg the

question whether a lower dose could be used in younger patients.

DTIL stock could re-rate meaningfully by YE26 post PBGENE-DMD clinical DTIL

Precision BioSciences, Inc. update

Sector: Biotechnology

Recall, cohort 1 is currently enrolling patients between the ages of two to seven. PBGENE-

Company Update DMD is delivered via muscle tropic AAV9 at 1e14, with ~90% full capsids. The vector

encodes two ARCUS nucleases that catalyze the excision of exons 45–55 of the dystrophin Share Price $8.11

gene. Note, muscle biopsies are expected to be collected at Month 3 and Month 12.